Inhibitor Therapeutics (OTCMKTS:INTI) Announces Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) issued its quarterly earnings results on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.

Inhibitor Therapeutics Stock Up 8.7 %

INTI stock traded up $0.00 during midday trading on Friday, hitting $0.06. The company’s stock had a trading volume of 147,145 shares, compared to its average volume of 40,416. The firm has a 50-day simple moving average of $0.06 and a 200-day simple moving average of $0.07. The firm has a market capitalization of $10.34 million, a P/E ratio of -6.00 and a beta of -0.55. Inhibitor Therapeutics has a 52-week low of $0.04 and a 52-week high of $0.14.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.